Back

Inflammation and cholesterol associated residual cardiovascular risk and its dependence on chronic kidney disease in statin treated patients with coronary artery disease

30 August 2024 (08:00 - 08:50)
Organised by: Logo
Congress Presentation Part of: Lipid-lowering treatment: impact on the atherosclerotic plaque and outcomes Epidemiology, Prognosis, Outcome ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Christopher Blaum

University Heart and Vascular Centre Hamburg (UHZ), Hamburg (Germany)

8 More presentations in this session

Presentation thumbnail
Lower rate of ischemic events with PCSK9 inhibition in patients with atherosclerotic cardiovascular disease but without prior ischemic events
Professor D. Bhatt (New York City, US)
Abstract Slides Video
Presentation thumbnail
Strike early-strike strong lipid-lowering strategy with PCSK9i in ACS patients. Real-world evidence from AT-TARGET-IT registry.
Doctor F. Marzano (Naples, IT)
Abstract Slides Video
Presentation thumbnail
PCSK9 inhibitors and coronary atherosclerotic plaque modification: a meta-analysis
Doctor P. Theofilis (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Functional improvement of non-infarct related coronary artery stenosis by extensive LDL-C reduction with a PCSK9 antibody: the FITTER trial, microvascular function analysis
Mr J. Los (Nijmegen, NL)
Abstract Slides Video
Presentation thumbnail
Estimated impact of inclisiran treatment on hyperlipidemia prevalence and cardiovascular disease events in NHANES dataset
Professor Y. Zhang (Shanghai, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Lipid-lowering treatment: impact on the atherosclerotic plaque and outcomes

The Event

Event poster

ESC Congress 2024

30 August 2024 08:00 CET
You may be interested in
thumbnail
Congress Presentation
Clinical outcomes according to residual cholesterol and inflammatory risk in patients undergoing PCI
thumbnail
Congress Presentation
Residual inflammation, cholesterol risks and rates of major cardiovascular events in routinely cared patients with atherosclerotic cardiovascular disease
thumbnail
Congress Presentation
Residual inflammatory risk: what is it and what can we do about it?

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources